In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...

Initiating methotrexate within 2 years of a psoriasis diagnosis is associated with a reduced risk of progressing to PsA.

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

Almirall has announced that it will be hosting the 16th edition of its Skin Academy, a conference that encourages ...

Although Biocon Biologics has not yet announced the likely price of the drug in India, as it is too early and local approval ...

Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This ...

Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

Research is ongoing as to whether treating psoriasis with biologics can lower the risk of PsA, and the results of studies have been mixed. There's some evidence that early psoriasis treatment with ...